Munich - Delayed Quote • EUR Chimerix Inc (CXF.MU) Follow Compare 3.6700 -0.0300 (-0.81%) At close: January 24 at 5:26:31 PM GMT+1 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for CXF.MU 1D 5D 5.16% 1M 26.99% 3M 358.18% 6M 345.93% YTD 5.01% 1Y 337.32% 5Y 103.89% All -85.49% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CXF.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) US Penny Stocks To Watch In January 2025 Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing Chimerix to Speak Today at The White House Cancer Moonshot Forum Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma 3 Promising Penny Stocks With Market Caps Under $2B In US Sector Update: Health Care Stocks Decline Late Afternoon Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting